Logo

American Heart Association

  13
  0


Final ID: MDP665

Successful Left Atrial Appendage Occlusion (LAAO) with WATCHMAN FLX via Transhepatic Approach

Abstract Body (Do not enter title and authors here): Left atrial appendage occlusion (LAAO) with the WATCHMAN FLX (Boston Scientific) has been proven to reduce stroke risk in patients with paroxysmal atrial fibrillation (PAF). Certain circumstances may preclude LAAO1. In this case, transhepatic vein access was used to successfully deploy a WATCHMAN FLX in a 72 year old male with PAF not on anticoagulation due to recent subdural hemorrhage and recurrent bilateral lower extremity deep venous thrombosis (DVT) post IVC filter placement. Recent attempt at LAAO was unsuccessful due to total occlusion of bilateral femoral veins (Figure 1 A-B) and inability to cross the IVC.
Access to the inferior branch of the right hepatic vein was achieved by micropuncture technique at the right mid-axillary line at the level of the 12th rib, which was confirmed by venogram (Figure 2A). The 4F microsheath was upsized to 16F. Intraoperative TEE was used for device sizing and delivery (Figure 3A). The transseptal sheath and dilator were positioned in the right atrium at the level of the fossa ovalis (Figure 3B) before successfully crossing into the left atrium (Figure 2B). After confirming placement (Figure 3C), a pigtail catheter was positioned within the LAA (Figure 3D) and an angiogram was performed (Figure 2C). A 24 mm WATCHMAN FLX was partially unsheathed and positioned (Figure 3E). Repeat LAA angiogram was performed through the WATCHMAN delivery sheath (Figure 2D). A Tug test was performed. The device was released (Figure 3F). Repeat venogram was performed to confirm location (Figure 2E) of the access site, and coil embolization closure of the venotomy access site was performed (Figure 2F). The patient was discharged the following day on dual antiplatelet (aspirin, clopidogrel) without complication. Venous access via right hepatic vein is a viable option for LAAO using the WATCHMAN FLX device.
  • Charbonne, Gael  ( Kettering Health Main Campus , Kettering , Ohio , United States )
  • Card, Alex  ( Kettering Health Main Campus , Kettering , Ohio , United States )
  • Fischer, Karley  ( Kettering Health Main Campus , Kettering , Ohio , United States )
  • Mitiek, Omar  ( Kettering Health Main Campus , Kettering , Ohio , United States )
  • Valencia, Damian  ( Kettering Health Main Campus , Kettering , Ohio , United States )
  • Schwartz, Brian  ( Kettering Health Main Campus , Kettering , Ohio , United States )
  • Author Disclosures:
    Gael Charbonne: DO NOT have relevant financial relationships | Alex Card: DO NOT have relevant financial relationships | Karley Fischer: DO NOT have relevant financial relationships | Omar Mitiek: No Answer | Damian Valencia: DO NOT have relevant financial relationships | Brian Schwartz: No Answer
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:
More abstracts on this topic:
Analysis risk factors of long-term adverse outcomes and construction of nomogram based on fractional flow reserve for coronary artery disease patients with an intermediate stenosis

Li Fan Qi, Liu Qiming, Xiao Yichao

A randomized controlled trial of antithrombotic therapy in ischemic stroke patients with non-valvular atrial fibrillation and atherosclerosis: The ATIS-NVAF trial

Okazaki Shuhei, Uchida Kazutaka, Asakura Koko, Omae Katsuhiro, Yamamoto Haruko, Hirano Teruyuki, Toyoda Kazunori, Iguchi Yasuyuki, Noguchi Teruo, Okada Yasushi, Kitagawa Kazuo, Tanaka Kanta, Sakai Nobuyuki, Yamagami Hiroshi, Yazawa Yukako, Doijiri Ryosuke, Koga Masatoshi, Ihara Masafumi, Yamamoto Shiro, Kamiyama Kenji, Honda Yuko

More abstracts from these authors:
You have to be authorized to contact abstract author. Please, Login
Not Available